Home Biotechnology Regeneron Pharmaceuticals Inc.
R

Regeneron Pharmaceuticals Inc.

Profile managed by Bizz Id
United States 500+ employees 1988

Description

Biotechnology company that researches, develops and markets medicines for serious diseases. Its products and pipeline span eye, allergic and inflammatory, cancer, cardiovascular and metabolic, neurological, hematologic, infectious and rare diseases. It uses its in-house VelociSuite antibody platform and genetic medicine platforms.

Products

35 products
Aflibercept (ref. Eylea HD)

Brand: Eylea HD.

Aprobado FDA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Aflibercept: see suppliers →

Aflibercept (ref. Eylea)

Brand: Eylea.

Aprobado FDA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Aflibercept: see suppliers →

Alirocumab

Brand: Praluent.

Aprobado FDA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Alirocumab: see suppliers →

Amrecibart

Phase 3. REGN9933. Factor XI monoclonal antibody; stroke prevention in atrial fibrillation.

Under development

Finished product (FDF)

Verified on 2026-10-21

Amrecibart: see suppliers →

Atoltivimab + Maftivimab + Odesivimab

Brand: Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn).

Aprobado FDA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Atoltivimab: see suppliers → · Maftivimab: see suppliers → · Odesivimab: see suppliers →

Baloncibart

Phase 2. REGN7544. NPR1 antagonist monoclonal antibody; POTS and sepsis-induced hypotension.

Under development

Finished product (FDF)

Verified on 2026-10-21

Baloncibart: see suppliers →

Bremzalerbart + Atisnolerbart

Phase 3. REGN5713-5715. Bet v 1 monoclonal antibodies; birch allergy.

Under development

Finished product (FDF)

Verified on 2026-10-21

Bremzalerbart: see suppliers → · Atisnolerbart: see suppliers →

Cemiplimab

Brand: Libtayo (cemiplimab-rwlc). PD-1 monoclonal antibody. In development: early-stage intralesional CSCC (Phase 3); neoadjuvant CSCC, NSCLC and HCC (Phase 2).

Aprobado FDA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Cemiplimab: see suppliers →

Cenvacibart

Phase 3. REGN7508. Factor XI monoclonal antibody; VTE after total knee replacement, cancer-associated VTE, SPAF (Phase 3); thrombosis (Phase 2).

Under development

Finished product (FDF)

Verified on 2026-10-21

Cenvacibart: see suppliers →

Davutamig

Phase 2. REGN5093. Bispecific antibody to two distinct MET epitopes; MET-altered advanced NSCLC.

Under development

Finished product (FDF)

Verified on 2026-10-21

Davutamig: see suppliers →

Dupilumab

Brand: Dupixent. Monoclonal antibody to IL-4R alpha subunit. In development: pediatric asthma (2-5 years) and chronic pruritus of unknown origin (Phase 3); severe food allergy with linvoseltamab (Phase 1).

Aprobado FDA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Dupilumab: see suppliers →

Evinacumab

Brand: Evkeeza (evinacumab-dgnb).

Aprobado FDA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Evinacumab: see suppliers →

Fianlimab

Phase 3. LAG-3 monoclonal antibody; first-line metastatic and adjuvant melanoma (Phase 3); perioperative NSCLC and melanoma, first-line metastatic HNSCC (Phase 2).

Under development

Finished product (FDF)

Verified on 2026-10-21

Fianlimab: see suppliers →

Freneslerbart + Mevonlerbart

Phase 3. REGN1908-1909. Multi-antibody therapy to Fel d 1; cat allergy.

Under development

Finished product (FDF)

Verified on 2026-10-21

Freneslerbart: see suppliers → · Mevonlerbart: see suppliers →

Garetosmab

Brand: Pasatru (garetosmab-grts). Activin A monoclonal antibody; fibrodysplasia ossificans progressiva.

Aprobado FDA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Garetosmab: see suppliers →

Linvoseltamab

Brand: Lynozyfic (linvoseltamab-gcpt). BCMA x CD3 bispecific antibody; multiple myeloma (further lines in Phase 3).

Aprobado FDA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Linvoseltamab: see suppliers →

Marlotamig

Phase 2. REGN7075. EGFR x CD28 bispecific antibody; solid tumors.

Under development

Finished product (FDF)

Verified on 2026-10-21

Marlotamig: see suppliers →

Mibavademab

Phase 3. LEPR monoclonal antibody; generalized lipodystrophy and monogenic obesity (Phase 3); functional hypothalamic amenorrhea (Phase 2).

Under development

Finished product (FDF)

Verified on 2026-10-21

Mibavademab: see suppliers →

Nezastomig

Phase 2. REGN5678. PSMA x CD28 bispecific antibody; prostate cancer (Phase 2); combinations with cemiplimab (renal cell carcinoma) and REGN4336 (prostate) in Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

Nezastomig: see suppliers →

Odronextamab

Phase 3. CD20 x CD3 bispecific antibody; lymphoma (Phase 3); B-NHL (pivotal study, Phase 2).

Under development

Finished product (FDF)

Verified on 2026-10-21

Odronextamab: see suppliers →

Pozelimab

Brand: Veopoz (pozelimab-bbfg). C5 monoclonal antibody. In development: PNH and geographic atrophy in combination with cemdisiran (Phase 3).

Aprobado FDA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Pozelimab: see suppliers →

REGN10597 (PD-1 x IL2Ra)

Phase 1/2. PD1-IL2Ra bispecific; solid tumors.

Under development

Finished product (FDF)

Verified on 2026-10-21

REGN13335 (PDGF-B antagonist)

Phase 2. PDGF-B antagonist monoclonal antibody; pulmonary arterial hypertension.

Under development

Finished product (FDF)

Verified on 2026-10-21

REGN17372 (GPRC5D x CD28)

Phase 1. GPRC5D x CD28 bispecific antibody; multiple myeloma.

Under development

Finished product (FDF)

Verified on 2026-10-21

REGN20423 (anti-IL-13)

Phase 1. IL-13 monoclonal antibody; atopic dermatitis.

Under development

Finished product (FDF)

Verified on 2026-10-21

REGN20934 (anti-ActRIIA/B)

Phase 1. ActRIIA/B monoclonal antibody; obesity.

Under development

Finished product (FDF)

Verified on 2026-10-21

REGN4336 (PSMA x CD3)

Phase 1. PSMA x CD3 bispecific antibody, in combination with nezastomig; prostate cancer.

Under development

Finished product (FDF)

Verified on 2026-10-21

REGN5668 (MUC16 x CD28)

Phase 2. MUC16 x CD28 bispecific antibody; ovarian cancer.

Under development

Finished product (FDF)

Verified on 2026-10-21

REGN5837 (CD22 x CD28)

Phase 1. CD22 x CD28 bispecific antibody; B-NHL.

Under development

Finished product (FDF)

Verified on 2026-10-21

REGN7945 (CD38 x CD28)

Phase 1. CD38 x CD28 bispecific antibody; multiple myeloma.

Under development

Finished product (FDF)

Verified on 2026-10-21

REGN9533 (anti-factor XII)

Phase 1. Factor XII monoclonal antibody; healthy volunteers.

Under development

Finished product (FDF)

Verified on 2026-10-21

Sarilumab

Brand: Kevzara. Monoclonal antibody to IL-6R; collaboration with Sanofi. In development: systemic JIA (pivotal study, Phase 2).

Aprobado FDA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Sarilumab: see suppliers →

Trevogrumab

Phase 2. REGN1033. Myostatin (GDF8) monoclonal antibody; obesity.

Under development

Finished product (FDF)

Verified on 2026-10-21

Trevogrumab: see suppliers →

Ubamatamab

Phase 2. REGN4018. MUC16 x CD3 bispecific antibody; serous ovarian cancer, advanced NSCLC.

Under development

Finished product (FDF)

Verified on 2026-10-21

Ubamatamab: see suppliers →

Vonsetamig

Phase 1. REGN5459. BCMA x CD3 bispecific antibody; transplant desensitization in CKD and lupus nephritis.

Under development

Finished product (FDF)

Verified on 2026-10-21

Vonsetamig: see suppliers →

Contact company

Register for free to see this company’s contact details and get in touch.

Register - Free